1456889-80-7

Basic information

• Product Name: Dabigatran iMpurity E
• Synonyms: Dabigatran iMpurity E
• CAS NO: 1456889-80-7
• Molecular Formula: C20H22N4O3
• Molecular Weight: 366.41368
• Product Categories: benzimidazol;Dabigatran impurity
• Mol File: 1456889-80-7.mol

Chemical Properties

• Boiling Point: 588.0±48.0 °C(Predicted)
• Appearance: /
• Density: 1.22±0.1 g/cm3(Predicted)
• PKA: 5.58±0.25(Predicted)
• CAS DataBase Reference: Dabigatran iMpurity E(CAS DataBase Reference)
• NIST Chemistry Reference: Dabigatran iMpurity E(1456889-80-7)
• EPA Substance Registry System: Dabigatran iMpurity E(1456889-80-7)

Safety Data

• Hazardous Substances Data: 1456889-80-7(Hazardous Substances Data)

Upstream product

• 64-19-7 acetic acid 
• 212322-56-0 ethyl 3-{[{2-amino-1-(methylamino)phen-4-yl}carbonyl](pyridyn-2-yl)amino}propanoate 

Downstream Products

• 211915-06-9 dabigatran etexilate 
• 872728-81-9 N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl] amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-(2-pyridinyl)-β-alanine ethyl ester methanesulfonate 

Relevant articles and documents

SYNTHESIS OF DABIGATRAN

The present invention relates to a process for preparation of Dabigatran etexilate or pharmaceutically acceptable salt thereof. The present invention relates to novel compounds, in particular Ethyl-3-{[(2-formyl-l-methyl-lH-benzimidazole-5-yl) carbonyl] -(2-pyridinyl) amino} propanoate and Ethyl-3-{[(2-dichloromethyl-l-methyl -lH-benzimidazole-5-yl)carbonyl]- (2-pyridinyl) amino}propanoate and process for preparation thereof. The present invention further relates to the use of these novel compounds in the preparation of Dabigatran etexilate or pharmaceutically acceptable salt thereof.

Synthesis, characterization and suppression of impurities during optimization of dabigatran etexilate

The synthetic methods for two impurities of dabigatran etexilate are firstly described, and both of two impurities are characterized by NMR and MS spectral data. The suppression of impurities as well as the optimization process of dabigatran etexilate is also disclosed.